Metformin tied to better clinical outcomes in CKD, CHF, CLD

January 4, 2017

(HealthDay)—For patients with chronic kidney disease (CKD), congestive heart failure (CHF), or chronic liver disease (CLD) with hepatic impairment, metformin use is associated with improvements in clinical outcomes, according to a review published online Jan. 3 in the Annals of Internal Medicine.

Matthew J. Crowley, M.D., from the Durham Veterans Affairs Medical Center and Duke University School of Medicine in North Carolina, and colleagues synthesized data addressing outcomes of use in patients with type 2 diabetes and moderate to severe CKD, CHF, or CLD with hepatic impairment. Data were included from studies that compared diabetes regimens that included metformin with those that did not, and reported all-cause mortality, major adverse cardiovascular events, and other outcomes of interest.

The researchers found that metformin use correlated with reduced all-cause mortality in patients with CKD, CHF, or CLD with hepatic involvement on the basis of quantitative and qualitative syntheses involving 17 observational studies. In patients with CKD or CHF, metformin use correlated with fewer heart failure readmissions.

"Metformin use in patients with moderate CKD, CHF, or CLD with hepatic impairment is associated with improvements in key ," the authors write. "Our findings support the recent changes in metformin labeling."

Explore further: Greater drop in hemoglobin A1c with empagliflozin plus metformin

More information: Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Related Stories

Varying safety of add-on second-line T2DM treatments

June 17, 2016

(HealthDay)—For patients with type 2 diabetes who are taking metformin, the risk of cardiovascular events and mortality varies with the addition of different second-line therapies, according to a study published online ...

Recommended for you

Overweight affects DNA methylation

December 22, 2016

The extra pounds you gain during the holidays will not only show up on your hips but will also affect your DNA. This is the result of a large-scale international study coordinated by Helmholtz Zentrum München, a partner ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.